479 related articles for article (PubMed ID: 25713386)
1. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption.
Rothenberger MK; Keele BF; Wietgrefe SW; Fletcher CV; Beilman GJ; Chipman JG; Khoruts A; Estes JD; Anderson J; Callisto SP; Schmidt TE; Thorkelson A; Reilly C; Perkey K; Reimann TG; Utay NS; Nganou Makamdop K; Stevenson M; Douek DC; Haase AT; Schacker TW
Proc Natl Acad Sci U S A; 2015 Mar; 112(10):E1126-34. PubMed ID: 25713386
[TBL] [Abstract][Full Text] [Related]
2. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.
Lerner P; Guadalupe M; Donovan R; Hung J; Flamm J; Prindiville T; Sankaran-Walters S; Syvanen M; Wong JK; George MD; Dandekar S
J Virol; 2011 May; 85(10):4772-82. PubMed ID: 21345945
[TBL] [Abstract][Full Text] [Related]
3. Defining total-body AIDS-virus burden with implications for curative strategies.
Estes JD; Kityo C; Ssali F; Swainson L; Makamdop KN; Del Prete GQ; Deeks SG; Luciw PA; Chipman JG; Beilman GJ; Hoskuldsson T; Khoruts A; Anderson J; Deleage C; Jasurda J; Schmidt TE; Hafertepe M; Callisto SP; Pearson H; Reimann T; Schuster J; Schoephoerster J; Southern P; Perkey K; Shang L; Wietgrefe SW; Fletcher CV; Lifson JD; Douek DC; McCune JM; Haase AT; Schacker TW
Nat Med; 2017 Nov; 23(11):1271-1276. PubMed ID: 28967921
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of productive and latent HIV infection in lymphatic tissue and peripheral blood during triple-drug combination therapy with or without additional interleukin-2.
Stellbrink HJ; Hufert FT; Tenner-Racz K; Lauer J; Schneider C; Albrecht H; Racz P; van Lunzen J
Antivir Ther; 1998; 3(4):209-14. PubMed ID: 10682140
[TBL] [Abstract][Full Text] [Related]
5. HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.
Pinkevych M; Cromer D; Tolstrup M; Grimm AJ; Cooper DA; Lewin SR; Søgaard OS; Rasmussen TA; Kent SJ; Kelleher AD; Davenport MP
PLoS Pathog; 2015 Jul; 11(7):e1005000. PubMed ID: 26133551
[TBL] [Abstract][Full Text] [Related]
6. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
Zhang L; Ramratnam B; Tenner-Racz K; He Y; Vesanen M; Lewin S; Talal A; Racz P; Perelson AS; Korber BT; Markowitz M; Ho DD
N Engl J Med; 1999 May; 340(21):1605-13. PubMed ID: 10341272
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
8. Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.
Pinkevych M; Fennessey CM; Cromer D; Tolstrup M; Søgaard OS; Rasmussen TA; Keele BF; Davenport MP
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118123
[TBL] [Abstract][Full Text] [Related]
9. Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30.
Hogan LE; Vasquez J; Hobbs KS; Hanhauser E; Aguilar-Rodriguez B; Hussien R; Thanh C; Gibson EA; Carvidi AB; Smith LCB; Khan S; Trapecar M; Sanjabi S; Somsouk M; Stoddart CA; Kuritzkes DR; Deeks SG; Henrich TJ
PLoS Pathog; 2018 Feb; 14(2):e1006856. PubMed ID: 29470552
[TBL] [Abstract][Full Text] [Related]
10. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells.
Stellbrink HJ; van Lunzen J; Hufert FT; Fröschle G; Wolf-Vorbeck G; Zöllner B; Albrecht H; Greten H; Racz P; Tenner-Racz K
AIDS; 1997 Jul; 11(9):1103-10. PubMed ID: 9233456
[TBL] [Abstract][Full Text] [Related]
11. Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection.
Evering TH; Mehandru S; Racz P; Tenner-Racz K; Poles MA; Figueroa A; Mohri H; Markowitz M
PLoS Pathog; 2012 Feb; 8(2):e1002506. PubMed ID: 22319447
[TBL] [Abstract][Full Text] [Related]
12. Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART.
Puertas MC; Noguera-Julian M; Massanella M; Pou C; Buzon MJ; Clotet B; Stevenson M; Paredes R; Blanco J; Martinez-Picado J
Retrovirology; 2016 Aug; 13(1):51. PubMed ID: 27484989
[TBL] [Abstract][Full Text] [Related]
13. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
[TBL] [Abstract][Full Text] [Related]
14. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ; Hatano H; Bacon O; Hogan LE; Rutishauser R; Hill A; Kearney MF; Anderson EM; Buchbinder SP; Cohen SE; Abdel-Mohsen M; Pohlmeyer CW; Fromentin R; Hoh R; Liu AY; McCune JM; Spindler J; Metcalf-Pate K; Hobbs KS; Thanh C; Gibson EA; Kuritzkes DR; Siliciano RF; Price RW; Richman DD; Chomont N; Siliciano JD; Mellors JW; Yukl SA; Blankson JN; Liegler T; Deeks SG
PLoS Med; 2017 Nov; 14(11):e1002417. PubMed ID: 29112956
[TBL] [Abstract][Full Text] [Related]
16. Establishment of a Novel Humanized Mouse Model To Investigate
Flerin NC; Bardhi A; Zheng JH; Korom M; Folkvord J; Kovacs C; Benko E; Truong R; Mota T; Connick E; Jones RB; Lynch RM; Goldstein H
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626677
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Neumann AU; Tubiana R; Calvez V; Robert C; Li TS; Agut H; Autran B; Katlama C
AIDS; 1999 Apr; 13(6):677-83. PubMed ID: 10397562
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
19. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
[TBL] [Abstract][Full Text] [Related]
20. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy.
Zhang L; Chung C; Hu BS; He T; Guo Y; Kim AJ; Skulsky E; Jin X; Hurley A; Ramratnam B; Markowitz M; Ho DD
J Clin Invest; 2000 Oct; 106(7):839-45. PubMed ID: 11018071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
